Loading…
Almost every serum sold on proof-led claims points at a study. Very few buyers ever look at one. This article walks through a single published example, not because the ingredient is in our range, but because reading it teaches you how to weigh the claims you meet everywhere else.
Duan and Lu published work in the Journal of Cosmetic Dermatology in 2025 describing HY-1, a peptide conjugate presented as a multifunctional skincare ingredient with antiaging and skin repair properties.
In a small 28-day clinical study of 49 adults with wrinkle concerns, a cream containing the HY-1 peptide conjugate was reported to be associated with dermatologist-assessed improvements in firmness and wrinkle appearance. The paper also reported antioxidant and anti-inflammatory activity in vitro.
That is the entire finding. Now look at what each part of it is worth.
49 people is a small sample. Small studies produce noisier results. With few participants, ordinary variation between individuals can look like an effect, and the effect size you measure is less likely to hold up when someone repeats the work at scale. Small is not the same as wrong. It is the same as uncertain.
28 days is a short window. Four weeks is roughly one cycle of surface skin turnover. It is long enough to detect changes in hydration and comfort, and short for claims about wrinkles, which is the harder endpoint here.
Dermatologist-assessed is a human judgement. A trained clinician grading firmness is more rigorous than a participant rating themselves, and it is still a person looking at skin and assigning a score, not an instrument returning a number. The published description does not tell us whether the assessors were blinded to who received what, and that distinction changes how much confidence the grading deserves.
In vitro is not on people. Antioxidant and anti-inflammatory activity measured in cells or in a dish tells you the molecule can do something under laboratory conditions. It does not tell you that it does that thing in your skin, through a formula, at the concentration used, after getting past the stratum corneum. In vitro results are the most commonly over-quoted evidence in ingredient marketing precisely because they sound decisive and are cheap to produce.
Useful hierarchy, roughest to strongest:
A plain guide to what the skin barrier is, what damages it, and how a short, single-ingredient serum routine can support it without a twelve-step shelf.
How beta-glucan and hyaluronic acid differ as humectants, which situations tend to suit each, and why the answer often depends on your climate and your moisturiser.
Why serum-strength actives are moving from face to body, what a body serum can reasonably do, and when a good body lotion is the better buy.
Most skincare claims live on rungs one and two. That is not scandalous, it is the economics of the category. It only becomes a problem when a rung-one result is sold with rung-four confidence.
When you see a clinical claim, ask five questions: how many people, for how long, versus what control, measured how, and was it topical on humans or activity in a dish. If the page will not tell you, the claim is a mood rather than a finding.
We are applying that standard to ourselves. Where we have proof, we will name the study and its limits. Where we do not, we will say that an ingredient is widely used and well tolerated and leave it there, because inventing the rest is how the category lost the right to the word clinical in the first place.